Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 11;40(4):410-423.e7.
doi: 10.1016/j.ccell.2022.03.005.

Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers

Affiliations
Free article

Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers

Chunhong Zheng et al. Cancer Cell. .
Free article

Abstract

Tumor-infiltrating neoantigen-reactive T cells can mediate regression of metastatic gastrointestinal cancers yet remain poorly characterized. We performed immunological screening against personalized neoantigens in combination with single-cell RNA sequencing on tumor-infiltrating lymphocytes from bile duct and pancreatic cancer patients to characterize the transcriptomic landscape of neoantigen-reactive T cells. We found that most neoantigen-reactive CD8+ T cells displayed an exhausted state with significant CXCL13 and GZMA co-expression compared with non-neoantigen-reactive bystander cells. Most neoantigen-reactive CD4+ T cells from a patient with bile duct cancer also exhibited an exhausted phenotype but with overexpression of HOPX or ADGRG1 while lacking IL7R expression. Thus, neoantigen-reactive T cells infiltrating gastrointestinal cancers harbor distinct transcriptomic signatures, which may provide new opportunities for harnessing these cells for therapy.

Keywords: adoptive cell therapy; bile duct cancer; cancer immunotherapy; gastrointestinal cancers; neoantigen; pancreatic cancer; single-cell RNA-seq; tumor-infiltrating lymphocytes.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests E.T. is on the scientific advisory board of PACT Pharma, Genocea Biosciences, and Turnstone Biologics. C.B.B. reports a consultant/advisory relationship with BMS, has stock ownership in and is on the scientific board of PrimeVax, and is on the scientific board of BioAI and LunaPhore. Other authors declare no competing interests.

Comment in

  • Tracking down tumor-specific T cells.
    Reading J, Foster K, Joshi K, Chain B. Reading J, et al. Cancer Cell. 2022 Apr 11;40(4):351-353. doi: 10.1016/j.ccell.2022.03.007. Cancer Cell. 2022. PMID: 35413268

Substances

LinkOut - more resources